Randomized open label clinical trial in which 48 renal transplant recipients with
inflammation in the 6 month allograft biopsy will either continue usual immunosuppression or
receive monthly Actemra (Tocilizumab) infusions for 6 months in addition to usual
immunosuppression.
Phase:
Phase 2
Details
Lead Sponsor:
Flavio Vincenti University of California, San Francisco